Adding Indoximod to Pembrolizumab Boosts Immune Response in Melanoma

TOP - August 2017, Vol 10, No 3 - Immunotherapy
Phoebe Starr

Washington, DC—Adding the investigational drug indoximod, an indoleamine 2,3-dioxygenase (IDO) pathway inhibitor, to the checkpoint inhibitor pembrolizumab led to higher response rates in patients with advanced melanoma than what is reported with pembrolizumab monotherapy, said lead investigator Yousef Zakharia, MD, Clinical Assistant Professor of Internal Medicine, Division of Hema­tology, Oncology and Blood and Marrow Transplantation, University of Iowa, Iowa City, at the 2017 American Association for Cancer Research meeting.

The IDO pathway is a key player in cancerogenesis. Dr Zakharia presented the results of an interim analysis of a phase 2 clinical trial.

Previously, in the pivotal phase 3 KEYNOTE-006 clinical trial, the overall response rate (ORR) to first-line pembroliz­umab in advanced melanoma was 33%. By contrast, the ORR was 52% in the phase 2 study with the novel combination of indoximod plus pembrolizumab.

“These results justify moving the combination of indoximod plus pembrolizumab forward to a phase 3 trial,” said Dr Zakharia. “Several IDO inhibitors in development are being studied in multiple solid tumors and hematologic malignancies,” he said.

Study Details

The phase 2, open-label, single-arm study enrolled 102 patients with stage III (13%) or stage IV (87%) advanced, unresectable melanoma who received indoximod plus pembrolizu­mab until disease progression. Of these patients, 40 (87%) had cutaneous melanoma, 9 (15%) had ocular melanoma (a type of melanoma that has very poor response to any therapy), and 11 (18%) had nonocular melanoma.

Patients could switch to a second checkpoint inhibitor (primarily ipilimumab) at disease progression and continue receiving indoximod.

Of the 60 patients who were evaluable for response, 31 (52%) achieved ORR; 6 achieved a complete response (CR) and 25 achieved a partial response. Of the 51 patients with cutaneous or nonocular melanoma, 30 (59%) achieved ORR; 6 achieved a CR and 24 achieved a partial response. The disease control rate (ie, response plus stable disease) was 73% in the overall patient population and 80% in the group with cutaneous or nonocular melanoma.

“This is the largest publicly available data set on IDO inhibitors plus checkpoint inhibitors,” Dr Zakharia noted.

In this study, as in other studies of different therapies, patients with ocular melanoma had a poor response to the combination therapy.

“We had impressive responses in nonocular melanoma, with many patients near CR,” said Dr Zakharia. The majority of the responses occurred within the first months of treatment.

The indoximod combination was well-tolerated. The majority of adverse events were as expected, with few grade 3 adverse events and no grade 4 adverse events. Serious adverse events potentially related to indoximod therapy were reported in 4 patients (ie, grade 3 arthritis, gastritis, and hearing impairment; and grade 2 interstitial nephritis), and 3 of these patients discontinued treatment. No treatment-related deaths were reported.

Priming the Immune Response

Dr Zakharia and colleagues were not able to identify biomarkers for response in the patients studied to date, although there was a suggestion for an improved response with elevated PD ligand 1 (PD-L1) expression.

“One could arguably say that the combination appears to get a better response with higher PD-L1 expression, but this needs to be interpreted with caution,” he said.

The press conference moderator, Louis M. Weiner, MD, Director, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, called these results “exciting,” and, if validated, “would represent a real advance.”

“It’s too soon to tell, but the approach of priming the immune response with novel strategies looks promising,” said Dr Weiner. “It will be a vigorous competition among ways to manipulate checkpoint inhibitors, but we don’t know who will win,” he added.

Related Items
Emerging Safety Data with Checkpoint Inhibitors
Phoebe Starr
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Conference Correspondent
Psychological Distress in Patients with Cancer Warrants Attention
Phoebe Starr
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Conference Correspondent
Patients’ Chemotherapy-Related Side-Effect Concerns Have Evolved, But Hair Loss Remains Significant
Phoebe Starr
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Conference Correspondent
Increased Cancer Risk in Postmenopausal Women with Central Obesity
Phoebe Starr
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Conference Correspondent
Patients’ Fears of Radiation Side Effects Largely Unfounded
Phoebe Starr
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Conference Correspondent
Novel Drug “Home Run” for TRK Mutation–Positive Tumors
Phoebe Starr
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Emerging Therapies
Alectinib New Standard of Care for ALK-Positive Non–Small-Cell Lung Cancer
Phoebe Starr
TOP - November 2017, Vol 10, No 4 published on November 13, 2017 in Lung Cancer
Pembrolizumab Makes Inroads in Sarcoma Subtypes
Phoebe Starr
TOP - November 2017, Vol 10, No 4 published on November 13, 2017 in Immunotherapy, Online First
Abemaciclib, a New CDK4/CDK6 Inhibitor, Added to Fulvestrant Extends PFS in Advanced HR-Positive, HER2-Negative Breast Cancer
Phoebe Starr
TOP - November 2017, Vol 10, No 4 published on November 13, 2017 in Breast Cancer
Novel Drug “Home Run” for TRK Mutation–Positive Tumors
Phoebe Starr
TOP - November 2017, Vol 10, No 4 published on November 13, 2017 in Emerging Therapies
Last modified: August 2, 2017